The present study was designed to establish the cellular localization and expression of transforming growth factor ␤ (TGF␤) signaling pathway components, including TGF␤1 and ␤2; TGF␤ receptors type I (T␤RI) and II (T␤RII); and Smads 2, 3, 4, and 6 during gonadotropin-induced follicular maturation and ovulation in the mouse ovary. Immature 21-day-old mice were sequentially treated with recombinant human FSH, 5 IU daily for 3 days, and hCG once at Day 24 of life. Immunohistochemical experiments revealed a TGF␤1 staining in granulosa cells (GC) and theca interna cells (TIC) as well as in oocytes, whereas that of TGF␤2 was mainly localized in oocytes and GC. Strong immunostaining for both T␤RI and -RII was observed in the TIC and, to a lesser extent, in GC. Whereas oocytes did not exhibit any staining for T␤RII, their T␤RI immunostaining was strong. Smads were detected in oocytes, GC, and luteal cells and in a lesser amount in TIC; the immunostaining for Smad 4 was the strongest. Western blotting and reverse transcriptionpolymerase chain reaction analyses indicated that, in response to gonadotropins, TGF␤2, T␤RI, Smad 2 and Smad 4 mRNA and protein levels increased, while those of Smad 6 decreased in ovarian homogenates. In conclusion, these results show that, in a model of immature mouse exposed to a sequential gonadotropin treatment, FSH and LH increased the expression of the TGF␤ signaling system through the increase of TGF␤2, T␤RI, stimulatory Smad 2, and common Smad 4 expression, which occurred concomitantly with a decrease of the inhibitory Smad 6 expression.
INTRODUCTION
Peptides of the large transforming growth factor ␤ (TGF␤) superfamily regulate multiple biological processes in mammals, such as development, growth, differentiation, and apoptosis (reviewed in [1, 2] ). In the ovary, many members of the TGF␤ superfamily have been detected, such as anti-Müllerian hormone [3] , bone morphogenetic proteins (BMPs), growth differentiation factors [4] , inhibin subunits ␣ and ␤ [5] , and TGF␤s [6] . For TGF␤s, the signaling pathway is initiated by the binding of the ligand to cell-surface serine/threonine kinase receptors, type I and type II (T␤RI and T␤RII) [7] , that activate the Smad signaling pathway [8] . The Smads are a family of related intracellular proteins, ranging from about 400 to 500 amino acids in length, critical for transmitting to the nucleus signals from the receptor after binding of the ligand [9] . Smads are classified into three subfamilies: the receptor-regulated Smads 1, 2, 3, 5, 8, and 9; the common Smad 4; and the inhibitory Smads 6 and 7 (I-Smads).
In rodents, TGF␤1 and TGF␤2 have been imunolocalized in theca interna cells (TIC), granulosa cells (GC), and luteal cells as well as in oocytes of mice [6, 10] , rats [11] [12] [13] [14] , and hamsters [15, 16] . However, intensity level of TGF␤ immunostaining appears to be highly variable among species, cycle day, and stage of follicular development. In the presence of TGF␤s, T␤RI and T␤RII form a heterodimer that is essential in mediating the actions of TGF␤s (reviewed in [17] ). The T␤RI has been detected in GC and luteal cells of the mouse ovary, but the main sites of immunoreactive T␤RI are TIC and oocytes [6] . In mice, despite the fact that T␤RII protein has been localized at a high level in oocytes and at a lower level in TIC, GC, and luteal cells [6] , the T␤RII mRNAs have been localized at a strong level in TIC and at only a weak level in GC and oocytes [18] . Little information is available on the expression of Smad proteins in the ovary. Smad 2 protein has been localized in hen GC [19] ; in human oocytes [20] ; and in oocytes, GC, and TIC of both immature [21, 22] and adult rats [22] . Smad 3 mRNA has been detected in mouse GC [23] . Similar to Smad 2, Smad 3 [22] and 4 [21] proteins have also been localized to oocytes, GC, and TIC of both immature and cycling rats.
In laboratory rodents, the effects of TGF␤s on the ovary appear to be largely paracrine and generally enhance follicular growth [24] [25] [26] [27] . TGF␤s also alter ovarian steroidogenesis; they stimulate progesterone synthesis in rat ovaries [28] but inhibit androgen production by TIC [28] .
The gonadotropins LH and FSH are major regulators of ovarian function, but there are no data related to the hormonal regulation of TGF␤s, T␤Rs, and Smads mRNA and proteins in mice. In the hamster ovary, FSH and LH stimulate the production of TGF␤2 and TGF␤1, respectively [15] . FSH has been shown to inhibit TGF␤2 expression [29] and production [30] by rat GC cultured in vitro. LH, which inhibits TGF␤2 expression in rat GC, has either no effect on [12] or inhibits [30] TGF␤1 production by TIC. Taken together, available data indicate that the relationships between the endocrine system and the expression of different components of the ovarian TGF␤ system remain to be clarified.
The present study was undertaken to test the hypothesis that the complete TGF␤ system, including the signaling proteins Smads, is expressed in the mouse ovary and is regulated by gonadotropins. Consequently, 1) the cellular localization of TGF␤1, TGF␤2, T␤RI, and T␤RII and Smads 2, 3, 4, and 6 was determined in the mouse ovary. Regulated Smads 2 and 3 were investigated because they are phosphorylated by activated activin and TGF␤ receptors whereas Smads 1, 5, and 8 are phosphorylated by activated BMP-receptors [21] . 2) Expression of TGF␤1, TGF␤2, T␤RI, T␤RII, and Smads 2, 3, 4, and 6 was analyzed in terms of mRNA and protein by using as a model immature mice sequentially treated with gonadotropins FSH and LH/hCG. 
MATERIALS AND METHODS

Animals and Treatments
RNA Extraction
Total RNA was extracted from whole ovaries with TRIzol reagent, a monophasic solution of phenol and guanidine isothiocyanate. This reagent is an improvement of the single-step RNA isolation developed by Chomczynski and Sacchi [31] . The amount of RNA was estimated by spectrophotometry at 260 nm.
Reverse Transcription
Single-stranded cDNAs were obtained from reverse transcription (RT) of 2 g of total RNA using random hexanucleotides as primers (5 M) in the presence of deoxynucleotide triphosphates (250 M) (Invitrogen, Cergy-Pontoise, France), dithiothreitol (10 mM) (Life Technologies, Eragny, France), and Moloney murine leukemia virus reverse transcriptase (10 U/l) (Life Technologies) for 1 h at 37ЊC.
Polymerase Chain Reaction Coamplification Analysis
Complementary DNAs (2 l RT mixture) were amplified by polymerase chain reaction (PCR) with Taq polymerase (0.025 U/l) (Promega, Charbonnière-les-Bains, France), deoxynucleotides (250 M), 0.75 Ci [␣-33 P]deoxy-ATP (Amersham, Buckinghamshire, UK), specific primers (0.5 M) and ␤-actin primers (forward: TTGCTGATCCACATCTGCTG; reverse: GACAGGATGCAGAAGGAGAT). The mixture was first heated at 94ЊC for 5 min followed by different numbers of cycles (n) of 30 sec each at 94ЊC, 30 sec at melting temperature (Tm), 30 sec at 72ЊC, and 7 min at 72ЊC (see Table 1 ). The amplification was performed in a thermocycler (PCR express; Hybaid, Middlesex, UK). The n, the Tm, and the ␤-actin concentrations were determined for each pair of primers after having tested temperatures between 50 and 70ЊC, cycle number between 20 and 40, and ␤-actin concentration between 10 and 200 nM. PCR products were separated on an 8% polyacrylamide gel. Dried gels were exposed to phosphor screens (Packard, Meriden, CT). Intensity of bands was estimated by densitometric scanning using the Cyclone Storage Phosphor scanner (Packard). The data are expressed as interest molecule:␤-actin mRNA ratio.
PCR analyses were carried out from the logarithmic phase of amplification. PCR-amplified products were checked by direct sequencing (ABI Prism; 310 genetic analyzer; Applied Biosystems, Courtaboeuf, France). RT-PCR primers were designed inside separate exons to avoid any bias caused by residual genomic contamination. Moreover, for all primers, no amplification was observed when PCR was performed on RNA preparations.
Western Blot Analysis
Protein was extracted by mechanical homogenization of ovaries in the presence of 200 l ice-cold hypotonic buffer (25 mM Tris-HCl, pH 7.4, 1 mM EDTA, protease inhibitor cocktail 1% [Sigma, l'Isle d'Abeau, France]). Protein concentrations were obtained by using a colorimetric Bradford method.
Proteins (30 g) were resolved on 12% SDS/polyacrylamide gels and electrophoretically transferred to nitrocellulose membranes (Hybond-C extra; Amersham, Les Ulis, France) using 25 mM Tris and 185 mM glycine (pH 8.3) containing 20% methanol. The transfer was performed at a constant voltage of 100 V for 2 h. After transfer, the membranes were incubated in blocking buffer (tris-buffered saline [TBS] buffer containing 10% fat-free dry milk) for 1 h at room temperature. The membranes were rinsed (3 ϫ 10 min) with TBS/Tween 20 0.1% and incubated with primary antibodies (TGF␤1, TGF␤2, T␤RII, Smads 2 and 3: 0.4 g/ml, Smads 4 and 6: 0.2 g/ml, T␤RI: 0.1 g/ml) overnight at 4ЊC. The membranes were rinsed with TBS/Tween 20 0.1% (3 ϫ 10 min) and then incubated with horseradish peroxidase-labeled goat or rabbit antibodies (1:2000) as appropriate. Bound antibodies were detected by chemiluminescence using a Covalab kit (CovalAb; Oullins, France) and Biomax MR-1 film (Eastman Kodak Co., Rochester, NY). The protein loading was checked by reprobing the blot with an actin antibody (1:500). The molecular weight of each protein was determined using biotinylated protein markers (CovalAb). This allowed validation of all antibodies used.
Immunohistochemistry
Paraffin sections (5 m) of either 10% neutral formalin-or Bouinfixed ovaries were mounted on polysin-coated glass slides (Polysin; Men-
Immunolocalization of TGF␤1 and TGF␤2 in the 21-to 26-dayold mouse ovary. Bar ϭ 70 m. O, Oocyte; GC, granulosa cells; TIC, theca-interna cells; P, primordial follicles. A) In control section where the primary antibody has been omitted and replaced by the antibody diluent, no immunostaining is observed (Bouin fluid fixation). B) The immunostaining for TGF␤1 in a 26-day-old mouse is strong in primordial oocytes (inset, bar ϭ 12 m), moderate in GC and growing oocytes, and weak in TIC (neutral formalin fixation). C) The immunostaining for TGF␤2 in a 21-day-old mouse is strong in primordial oocytes (inset, bar ϭ 12 m), moderate to strong in growing oocytes, moderate in GC from some but not all antral follicles (AF); it is weak in GC from early growing follicles (early GF) and in TIC (neutral formalin fixation). D) By 48 h after the first r-hFSH injection, the TGF␤2 immunostaining is strong in GC of all growing follicles and in oocytes and weak in TIC (neutral formalin fixation). zel-Glaser, Braunscheig, Germany). Sections were deparaffinized in xylen, hydrated, treated 20 min at 98ЊC in pH 6 citric buffer, rinsed in osmosed water (2 ϫ 5 min), washed (2 ϫ 5 min) in PBS Tween 20 0.1%, then incubated 10 min at 37ЊC in the peroxidase blocking reagent (DAKO, Trappes, France), washed (2 ϫ 5 min) in PBS-Tween 20 0.1%. After which the primary antibody, appropriately diluted 1:100-1:200 (1-2 g/ ml) was added and the sections incubated overnight at 4ЊC. Dose-response studies indicated that these dilutions of the antibodies gave optimal labeling results. When possible, several primary antibodies of either different origins or lots were used. Each of them was tested on both Bouin fluid and neutral formalin-fixed sections. When different staining between the two fixative types was observed, the primary antibody was tested on frozen sections postfixed in glacial acetone for 5 min. Immunohistochemistry was subsequently performed on the fixed sections that displayed the same immunostaining as the frozen sections. Each selected antibody was controlled by Western blotting to ensure that only one band at the expected molecular weight for the peptide against which it was directed was obtained. The selected antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA) and were the following: TGF␤1 (sc-146, lot E170), TGF␤2 (sc-090, lot BO603), T␤RI (sc-398, lot D135), T␤RII (sc-220, lot E222), Smad 2 (sc-6200, lot AO603), Smad 3 (sc-6202, lot L1702), Smad 4 (sc-1908, lot K238), and Smad 6 (sc-6034, lot L111). After incubation with the primary antibody, the sections were rinsed, washed (2 ϫ 5 min) in PBS-Tween 20 0.1%, then incubated 30 min at 37ЊC in the presence of the secondary antibody. For rabbit polyclonal antibodies (TGF␤2, T␤RI, and T␤RII), we used secondary rabbit immunoglobulins attached to a peroxidase-conjugated polymer backbone (Envision ϩ kit; DAKO). After incubation with the secondary antibody, the sections were rinsed; washed (2 ϫ 5 min) in PBS-Tween 20 0.1%; incubated 10 min at room temperature with AEC (3-amino-9-ethylcarbazole, DAKO), which generated a red color at the site of peroxidase activity; rinsed; washed (2 ϫ 5 min) in osmosed water; and then the nuclei were counterstained with Mayer hematoxylin (DAKO). For goat (TGF␤1 and Smads) polyclonal antibodies, we slightly modified the procedure mentioned above for rabbit antibodies by incubating the sections 30 min at 37ЊC in the presence of a rabbit anti-goat serum (DAKO) diluted at 1: 1000 just before incubation with the secondary antibody. Sections were coverslip mounted using Faramount (DAKO). Control sections received either buffer or serum (goat or rabbit, as appropriate) diluted appropriately, in place of the primary antibody. For each control or treatment day, one ovary from five mice was used, two to four sections per ovary were examined for each antibody. The intensity of the immunostaining was graded as weak, moderate, or strong.
FIG. 2. Effect of gonadotropins on
Follicles were classified as follows: primordial follicles containing an oocyte surrounded by a single layer of flattened squamous GC; early growing follicles including primary, secondary, and preantral follicles; small antral follicles; and preovulatory follicles larger than 0.4 mm in diameter.
Data Analysis
All data are presented as the mean Ϯ SD of at least three separate RT-PCR and Western blot experiments for each animal. Statistical analyses A) The immunostaining for T␤RI in a 23-day-old mouse is strong in oocytes from primordial and growing follicles and in TIC, moderate in basal GC of some antral follicles, but weak in GC of most follicles (Bouin fluid fixation). B) By 48 h after the first r-hFSH injection, T␤RI immunostaining had increased to a moderate level in GC of all follicles and remains strong in both TIC and oocytes (Bouin fluid fixation). C) In an ovary sampled 48 h after hCG injection, the T␤RI immunostaining is strong in oocytes with a germinal vesicle (GV) whereas it is absent from oocytes displaying germinal vesicle breakdown (GVBD) in atretic follicles (Bouin fluid fixation). D) The immunostaining for T␤RII in a 23-day-old mouse is strong in TIC while the oocytes are not stained. In antral follicles, basal GC display a weak to moderate immunostaining while antral GC are weakly stained (Bouin fluid fixation).
were carried out by ANOVA and post hoc Bonferroni/Dunn test (Statview software; SAS Institute Inc., Cary, NC).
RESULTS
For all antibodies, the replacement of the primary antibody by either the antibody diluent (Fig. 1A) or rabbit or goat normal serum, as appropriate, led to absence of any immunostaining in all ovarian tissues.
TGF␤1 and TGF␤2
No significant changes were observed in ovarian TGF␤1 mRNA and protein levels in gonadotropin-treated mice when compared with control animals (data not shown). In control mice, the TGF␤1 immunostaining was similarly present at a moderate level in oocytes and GC, but was weak in TIC (Fig. 1B) . After sequential treatment with gonadotropins, neither immunolocalization of TGF␤1 nor its staining intensity were changed. Corpora lutea, which appeared after hCG treatment, were, similar to preovulatory follicles, stained at a moderate level.
In control mice, neither TGF␤2 mRNA nor TGF␤2 protein levels exhibited significant changes from Day 21 to Day 26 (Fig. 2) . In gonadotropin-treated animals, the ovarian levels of TGF␤2 mRNA were significantly increased as soon as 24 h after the first r-hFSH injection when compared with control values at Day 21 (P Ͻ 0.0006) and Day 23 (P Ͻ 0.0001); they reached a plateau by 72 h after the first r-hFSH injection (Fig. 2A) . The TGF␤2 protein levels increased significantly (P Ͻ 0.0001) only 72 h after the first r-hFSH injection and remained at the same level after hCG injection (Fig. 2B) . In control mice, the TGF␤2 immunostaining was mainly observed in oocytes of both nongrowing and growing follicles; it was weak in both TIC and GC, but sometimes, GC in some antral follicles displayed a moderate staining (Fig. 1C) . By 48 h after the first injection of r-hFSH, the TGF␤2 immunostaining increased in both early growing and antral follicles (Fig. 1D) ; after hCG injection, it was moderate to strong in corpora lutea. 
T␤RI and T␤RII
There were no changes in ovarian T␤RI mRNA and protein levels from Day 21 to Day 26 in control mice (Fig. 3) . By 48 h after the first r-hFSH injection, the ovarian levels of T␤RI mRNA and protein were significantly increased when compared with control values (P Ͻ 0.0001). A plateau was reached by 72 h after the first r-hFSH injection (Fig. 3) . In control mice, a strong T␤RI immunostaining was seen in both oocytes and TIC; it was weak in GC, but moderate in basal GC from some antral follicles (Fig. 4A) . Whereas the T␤RI immunostaining remained strong in both TIC and oocytes in response to both r-hFSH and hCG, by 48 h after the first injection of r-hFSH, it increased in GC (Fig. 4B ). When they were present, after hCG injection, the corpora lutea exhibited a moderate to strong immunostaining for T␤RI. Whereas the T␤RI immunostaining remained strong in oocytes exhibiting a germinal vesicle, it disappeared from oocytes displaying a germinal vesicle breakdown in atretic follicles (Fig. 4C) .
No significant changes were observed for either ovarian T␤RII mRNA or protein levels in gonadotropin-treated mice when compared with control animals (data not shown). T␤RII immunostaining was strong in TIC but absent in oocytes; it was weak in GC of growing follicles but stronger in basal than in antral GC (Fig. 4D) . The immunostaining for T␤RII changed neither after r-hFSH treatment nor after hCG injection.
Smads
In control mice, from Day 21 to Day 26, there were no significant changes in ovarian protein and mRNA levels for Smad 2 (Fig. 5) , Smad 3 (data not shown), Smad 4 (Fig.  6 ), and Smad 6 (Fig. 7) . From 48 h after the first r-hFSH injection onward, the ovarian levels of Smad2 mRNA and proteins were significantly increased (P Ͻ 0.0001) and reached a maximum by 72 h after the first r-hFSH injection (Fig. 5) . Whereas the treatment of mice with hCG did not induce any changes of Smad 2 mRNA levels, it induced a transitory decrease (P Ͻ 0.0001) of Smad 2 protein levels by 24 h after hCG. However, 48 h after hCG injection, these levels increased (P Ͻ 0.0001) back to those observed 72 h after the first r-hFSH injection (Fig. 5B) . In response to either FSH or hCG, the Smad 3 mRNA and protein levels did not exhibit any changes when compared with control values (data not shown).
The ovarian levels of Smad 4 mRNA significantly (P Ͻ 0.0001) increased 24 h after the first injection of r-hFSH and reached a plateau by 48 h after the first r-hFSH injection. The slight decrease of Smad 4 mRNA levels observed 24 h after hCG injection was not significant (Fig. 6A) . The levels of Smad 4 protein significantly (P Ͻ 0.0001) increased 48 h after the first injection of r-hFSH and reached a plateau 72 h after the first r-hFSH injection (Fig. 6B) . From 48 h after the first r-hFSH injection to 48 h after hCG injection, the ovarian Smad 6 mRNA levels continuously and significantly (P Ͻ 0.0001) decreased (Fig. 7A) . The ovarian Smad 6 protein levels were significantly (P Ͻ 0.0001) decreased by 72 h after the first r-hFSH injection and by 48 h after hCG injection when compared with levels at 24 and 48 h after the first r-hFSH injection and with control values. However, by 24 h after hCG, the Smad 6 protein levels were similar to control values (Fig. 7B) .
In the control mouse ovary, immunostaining for Smads 2, 3, 4, and 6 was observed in the same cell types. In oocytes and GC, immunostaining for Smads 2 (Fig. 8A ) and 4 ( Fig. 8C) was stronger than that for Smads 3 (Fig.  8B) and 6 (Fig. 8F) . For all Smads, the level of immunostaining was weak in TIC. There was a heterogeneous staining of GC between follicles; for Smads 2 and 4, the staining varied from weak to moderate, whereas for Smads 3 and 6, it varied from absent to weak. No relationships between follicle size and Smad immunostaining were observed. While the levels of immunostaining for Smads 3 and 6 did not consistently change in gonadotropin-treated mice when compared with control animals, those for Smads 2 and 4 ( Fig. 8D ) appeared stronger in gonadotropin-treated than in control mice. After hCG treatment, corpora lutea were positively stained for Smads, and the staining was the strongest for Smad 4 (Fig. 8E) .
DISCUSSION
This is, to our knowledge, the first report on the expression of the ovarian TGF␤ system, including ligands, receptors, and Smads, in terms of cellular immunolocalization as well as mRNA and protein levels in immature mice either untreated or following a sequential hormonal treatment with FSH and LH/hCG. Indeed, gonadotropic stimulation of the 21-day-old mouse ovary induces strong changes in the follicular population, leading to preovulatory maturation within 48-72 h [32] . During this time interval, GC actively proliferate, then differentiate when follicles reach the large antral stage. Thus, changes in levels of certain proteins and mRNA need to be considered in this context of both active follicular growth and terminal differentiation.
The localization of TGF␤1 protein in the immature ovary is consistent with previously published studies in the mouse [6, 10] , showing that this peptide is present in oocytes, TIC, and GC. The present data showing that TGF␤1 was regulated neither by FSH nor by hCG are also consistent with previous studies in immature rats [12] and with porcine ovarian cells [33] . However, they differ from a previous immunohistochemical study in the immature mouse where eCG was reported to decrease, whereas eCG plus hCG increased, the TGF␤1 immunostaining in TIC [10] .
TGF␤2 immunostaining was mainly detected in oocytes and at a lesser extent in GC, but it was very low in TIC. These data are in contrast with previous studies for the localization of TGF␤2 in either the TIC [6, 10] or the oocyte [6] , but are consistent with a high level of TGF␤2 mRNA in oocytes, but apparently none in TIC [18] . The TGF␤2 mRNA levels significantly increased from control levels as soon as 24 h after the first FSH injection, while those of the protein increased 48 h later. The TGF␤2 immunostaining, which was weak in GC from early growing follicles in control mice, became moderate by 48 h after the beginning of the FSH treatment. Taken together, our data are consistent with those of Roy et al. [15] , who observed that TGF␤2 protein is upregulated by FSH in hamster GC, but they appear to be contradictory with data from rats, where FSH has been reported to inhibit both total and active TGF␤ production by cultured GC from hypophysec- The immunostaining for Smad 2 in a 23-day-old mouse is strong in primordial oocytes, moderate in growing oocytes and GC, and weak in TIC. B) The immunostaining for Smad 3 in a 23-day-old mouse is weak to moderate in oocytes, GC, and TIC. C) The immunostaining for Smad 4 in a 23-day-old mouse is moderate to strong in both GC and oocytes of some, but not all follicles, and weak in TIC. D) By 48 h after the first FSH injection, the Smad 4 immunostaining appears to be increased in GC of all growing follicles, whereas it remains weak in TIC. E) By 48 h after hCG injection, the Smad 4 immunostaining is moderate to strong in both follicles and corpora lutea. F) The immunostaining for Smad 6 in a 23-day-old mouse is often strong in primordial oocytes but weak in growing oocytes, in TIC, and GC; however, in some follicles, GC show a moderate immunostaining.
tomized 21-day-old rats [30] . Nevertheless, in the latter experiment, GC were cultured in vitro and all TGF␤s were assayed, leading to the impossibility of distinguishing which TGF␤ isoform production was altered by FSH. Finally, our data and previous studies performed in rodents show that important differences may exist in the regulation of TGF␤1 and TGF␤2 expression by gonadotropins. The presence of a cAMP regulatory element (CRE) sequence in the mouse TGF␤2 gene promoter [34, 35] suggests that TGF␤2 can be directly stimulated by FSH at the transcriptional level, although it cannot be excluded that FSH increases TGF␤2 mRNA stability, as previously demonstrated in cultured porcine Sertoli cells [36, 37] . No CRE sequence was noted in the promoter region of the mouse Tgfb1, but various data [38, 39] show that TGF␤1 regulation by the cAMP pathway is complex and remains unclear. Whether TGF␤1 stimulation requires different conditions than TGF␤2 to be activated by FSH and LH in the mouse ovary requires further studies, but the present data suggest that TGF␤2 may play a more critical role than TGF␤1 during mouse ovarian follicle development.
The immunolocalization of T␤RI in ovaries of 21-to 26-day-old mice is consistent with previously published data in the mouse [6] . For T␤RII, contrary to Juneja et al. [6] , who described strong immunostaining in oocytes while GC and TIC displayed moderate staining, the present data show that there is no immunostaining in oocytes, strong staining in TIC, and weak to moderate staining in GC. Consequently, our results are rather in agreement with the study showing that T␤RII mRNA is mainly expressed in TIC, barely expressed in GC, and not expressed in oocytes [18] .
In response to FSH, the T␤RI mRNA and protein levels increased 48 h after the first injection of FSH, whereas those for T␤RII did not change. Simultaneous with these changes, T␤RI immunostaining increased in GC. In response to hCG, T␤RI immunostaining as well as mRNA levels remained high. Taken together, the present findings indicate that, following a sequential FSH/LH-treatment, T␤RI but not T␤RII mRNA and protein levels increase. Because in the rat the promoter of the gene coding for T␤RI contains several Sp1 binding sites [40] , it appears that this gene may be directly regulated by gonadotropins. However, the possibility also exists that FSH increases T␤RI mRNA via an increase in TGF␤ ligand levels because, in various cellular models, TGF␤ increases T␤RI mRNA levels [41, 42] .
The Smad proteins were mainly detected in oocytes and GC. Our data are consistent with those of Li et al. [19] , Osterlund et al. [20] , and Drummond et al. [21] , who detected Smad 2 in hen GC, in human oocytes, and in oocytes, GC, and TIC of immature 12-day-old rats, respectively. Similar to our own data, Drummond et al. [21] detected Smads 2 and 4 at similar levels in the same cell types. Smad 2 mRNA and protein levels become significantly different from control values after 48 h of FSH treatment. The decrease in Smad 2 protein levels observed by 24 h after hCG injection may have no physiological meaning; however, it cannot be excluded that hCG transitorily inhibits Smad 2 translation. Surprisingly, the situation in the mouse ovary seems to be different from that recently observed in immature and cycling rats [22] , where Smad 2 and 3 proteins are downregulated by equine CG, while hCG has a dual effect, being first inhibitory and then stimulatory. For Smad 4, the mRNA levels significantly and strongly increased 24 h after the beginning of FSH treatment whereas the levels of the protein became significantly different from control levels after 48 h of FSH treatment. For Smad 2 and Smad 4, the changes in protein levels can be corre-lated to the increasing number of large follicles possessing GC, exhibiting a moderate immunostaining for both Smads 2 and 4. Very little is known about the regulation of Smad proteins. Smad 2 is upregulated by TGF␤ in avian GC [19] and in mammary carcinoma cells treated with the anticancer agent perillyl alcohol [43] . There are therefore some lines of evidence showing that not only T␤Rs can be induced in response to TGF␤ action, but that Smad 2 can also be upregulated by TGF␤s. Given these different findings, we suggest, on one hand, that FSH stimulates TGF␤2 production and, on the other hand, that TGF␤2 may act on T␤RI and Smad 2 expression to enhance its own actions in the mouse ovary. Nevertheless, it remains possible that FSH directly stimulates Smad expression, especially that of Smad 4, mRNA levels of which were rapidly and strongly increased in response to FSH.
Changes in Smad 6 mRNA and protein levels occur later than do changes in Smads 2 and 4; the significant decreases in Smads 2 and 4 occur 48 h and 72 h after FSH treatment, respectively. The increase in Smad 6 protein back to control level observed by 24 h after hCG injection may have no physiological meaning; however, it cannot be excluded that hCG transitorily stimulates Smad 6 translation. In mice, Smad 6 forms stable associations with T␤RI and interferes with the phosphorylation of Smad 2 and the subsequent heteromerization with Smad 4 [44] . Surprisingly, contrary to the situation observed in various cellular models where I-Smads are activated to terminate either the TGF␤, the activin, or the BMP signaling [45] [46] [47] [48] , the present study shows that the I-Smad 6 is downregulated in response to a gonadotropin treatment, leading to amplification of the TGF␤ action on ovarian cells. This suggests that a transcriptional repressor for Smad 6 may be operating in response to gonadotropins in the mouse ovary. Emerging evidence suggests that TGF␤-inducible early gene (TIEG) is a transcriptional repressor that can downregulate the ISmad 7 gene expression, a process that is Smad 4 dependent [49] and may involve the activation of Smad 2 [50] . Because in the ovary of mice sequentially treated with gonadotropins, Smad 6 is downregulated, it remains also to be demonstrated if TIEG can act as a transcriptional repressor for Smad 6.
The present data show that TGF␤2, T␤RI, Smad 2, and Smad 4 mRNA and proteins from whole ovarian extracts increase in response to FSH, which induces terminal folliculogenesis in immature mice. In the mammalian ovary, FSH receptors are present only on GC. In response to FSH, TGF␤2, T␤RI, Smad 2, and Smad 4 showed increased immunostaining in GC of growing follicles, consequently, it can be assumed that mRNA and protein changes observed in whole ovarian extracts likely reflect changes at the GC rather than at the TIC or oocyte level.
Although the present study shows that TIC exhibit a strong immunostaining for T␤RI and T␤RII, these cells exhibit weak immunostaining for Smads. A similar observation has been previously made in both immature and cycling rats for Smad 2 and Smad 3 [22] . Consequently, despite many effects of TGF␤s on TIC having been reported in the literature (reviewed in [51] ), our data suggest that, in vivo, TICs have poor ability to respond to TGF␤, raising concerns about previous in vitro experiments. In addition, immunohistochemical observations of the present study have shown that oocytes contain T␤RI but not T␤RII, suggesting that the mouse oocyte may not be a target for TGF␤, contrary to the situation in rats [52, 53] .
In conclusion, the present study, showing that GC contain both TGF-␤ receptors and Smad signaling proteins, suggests that this tissue is the preferential ovarian target for TGF␤s either produced by itself (autocrine action) or by neighboring tissues (paracrine action). This study is, to our knowledge, the first report showing that a sequential gonadotropin treatment in the immature mouse can induce an autocrine loop leading to amplification of TGF␤ action at the ovarian level, via upregulation of T␤RI, Smads 2 and 4 expression and production, and downregulation of the ISmad 6 expression and production. Because GC are the only cells to possess FSH receptors, then LH receptors when they become preovulatory, it appears likely that this autocrine loop takes place at the GC level.
